Saphnelo (anifrolumab-fnia) - AstraZeneca
Anifrolumab for treatment-resistant paediatric amyopathic dermatomyositis: report of two cases. (PubMed, Clin Exp Rheumatol) - Sep 18, 2026 - No abstract available 
Journal • Dermatomyositis • Immunology • Myositis • Pediatrics
http://www.ncbi.nlm.nih.gov/pubmed/42752317
 
Andrea Taddio; Beatrice Lorenzon; Erica Valencic; Francesca Nicolardi; Gloria Fadanelli; Serena Pastore
 
Sep 18, 2026
 
Prev Next